Mazer and Keegan have performed in vivo studies of Tregitope treatment in airway disease following induction of allergy in OVA-sensitized mice [33 and unpublished studies], Mingozzi and High have performed in vitro CD8+ T cell assays using both AAV and EBV antigens [34], and Elyaman and Khoury have administered Tregitopes with myelin oligodendrocyte glycoprotein (MOG) peptides in EAE [35]. Here, CD8A is linked to allergic disease.